Clinical Trial Update: Optimization of IV Ketamine for Treatment Resistant Depression [Phase 2]

View source ↗

Summary

Phase 2 trial assessing optimized IV ketamine dosing for treatment-resistant depression (and major depressive disorder); results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Treatment-resistant Depression

Drugs mentioned

• Ketamine (ketamine)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD) | Phase 2 | Status: COMPLETED | Results posted: 2014-01-31